Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [911]

How the WIN consortium achieves its goals

Prof Apostolia-Maria Tsimberidou - MD Anderson Cancer Centre, Houston, USA

How the WIN consortium achieves its goals ( Prof Apostolia-Maria Tsimberidou - MD Anderson Cancer Centre, Houston, USA )

KEYNOTE-028 and KEYNOTE-158: Pembrolizumab as treatment for advanced SCLC after...

Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea

KEYNOTE-028 and KEYNOTE-158: Pembrolizumab as treatment for advanced SCLC after two or more lines of prior therapy ( Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea )

Mesothelin-targeted CAR T-cell therapy safe, shows early promise in patients...

Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA

Mesothelin-targeted CAR T-cell therapy safe, shows early promise in patients with advanced solid tumours ( Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA )

Immune checkpoint inhibitor combination efficacious for patients with high...

Prof Sandip Patel - UC San Diego, San Diego, USA

Immune checkpoint inhibitor combination efficacious for patients with high-grade neuroendocrine carcinoma ( Prof Sandip Patel - UC San Diego, San Diego, USA )

HER2-targeted CAR T-cell therapy safe and showing promising antitumour activity...

Prof Shoba Navai - Baylor College of Medicine, Houston, USA

HER2-targeted CAR T-cell therapy safe and showing promising antitumour activity in patients with advanced sarcoma ( Prof Shoba Navai - Baylor College of Medicine, Houston, USA )

Gilteritinib improved survival for patients with acute myeloid leukaemia

Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA

Gilteritinib improved survival for patients with acute myeloid leukaemia ( Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA )

Latest updates in melanoma research

Dr Alexander van Akkooi - The Netherlands Cancer Institute, Amsterdam...

Latest updates in melanoma research ( Dr Alexander van Akkooi - The Netherlands Cancer Institute, Amsterdam, Netherlands )

Sequencing Sorafenib and Regorafenib in advanced hepatocellular carcinoma –...

Prof Josep Llovet, Dr Richard Finn

Sequencing Sorafenib and Regorafenib in advanced hepatocellular carcinoma – Brought to you by Oncology Knowledge into Practice ( Prof Josep Llovet, Dr Richard Finn )

Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma

Dr Stefanie Fischer - The Christie NHS Foundation Trust, Manchester, UK

Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma ( Dr Stefanie Fischer - The Christie NHS Foundation Trust, Manchester, UK )

KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non...

Prof David McDermott - Beth Israel Deaconess Medical Center, Boston, USA

KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma ( Prof David McDermott - Beth Israel Deaconess Medical Center, Boston, USA )

Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of...

Dr Sumit Subudhi - MD Anderson Cancer Center, Houston, USA

Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer ( Dr Sumit Subudhi - MD Anderson Cancer Center, Houston, USA )

CB-839 in combination with cabozantinib in patients with clear cell and...

Prof Funda Meric-Bernstam - MD Anderson Cancer Center, Houston, USA

CB-839 in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer ( Prof Funda Meric-Bernstam - MD Anderson Cancer Center, Houston, USA )

More from ecancer